Document:

Exhibit

Exhibit 10.1
NANOSTRING TECHNOLOGIES, INC.
AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT
This Amendment to Executive Employment Agreement (this “Amendment”) is made by and between Robert Bradley Gray (“Executive”) and NanoString Technologies, Inc., a Delaware corporation (the “Company” and together with Executive, the “Parties”) on the dates set forth below.
WHEREAS, the Parties previously entered into an employment agreement effective May 24, 2010 (the “Employment Agreement”); 
WHEREAS, the Company and Executive desire to amend certain provisions of the Employment Agreement related to severance benefits, as set forth below.
NOW, THEREFORE, for good and valuable consideration, the Parties agree that the Agreement is hereby amended as follows:
1.The Employment Agreement is hereby amended as follows:
The period at the end of the first sentence of Section 8(a) is replaced by the following:
“; provided, however, that if such Involuntary Termination occurs within twelve (12) months following a Change in Control (as defined in the Company’s 2013 Equity Incentive Plan), (i) Executive shall be entitled to a lump sum payment equal to twice Executive’s then-effective Base Salary and target bonus (less applicable withholding taxes) and (ii) if Executive elects continuation coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) within the time period prescribed pursuant to COBRA for Executive and Executive’s eligible dependents, the Company will reimburse Executive for the premiums necessary to continue  group health insurance benefits for Executive and Executive’s eligible dependents for a period of twenty-four (24) months following the date of Involuntary Termination, except that the right to future COBRA payments shall terminate the date upon which Executive ceases to be eligible for coverage under COBRA.”
2.Full Force and Effect.  To the extent not expressly amended hereby, the Agreement shall remain in full force and effect.
3.Entire Agreement.  This Amendment and the Agreement (and any other documents referenced therein) constitute the full and entire understanding and agreement between the Parties with regard to the subjects hereof and thereof.
4.Successors and Assigns.  This Amendment and the rights and obligations of the parties hereunder shall inure to the benefit of, and be binding upon, their respective successors, assigns, and legal representatives.
5.Governing Law.  This Amendment will be governed by the laws of the State of Washington (with the exception of its conflict of laws provisions).
(signature page follows)

IN WITNESS WHEREOF, each of the Parties has executed this Amendment as of the date set forth below.
	
		
	EXECUTIVE
	NANOSTRING TECHNOLOGIES, INC.

	By: /s/ R. Bradley Gray
	By: /s/ James A. Johnson

	Name:    R. Bradley Gray
	Name:    James A. Johnson

	 
	Title:    Chief Financial Officer

	 
	 

	Date:  August 4, 2017
	Date:  August 4, 2017Exhibit

Exhibit 10.2
NANOSTRING TECHNOLOGIES, INC.
AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT
This Amendment to Executive Employment Agreement (this “Amendment”) is made by and between Jim Johnson (“Executive”) and NanoString Technologies, Inc., a Delaware corporation (the “Company” and together with Executive, the “Parties”) on the dates set forth below.
WHEREAS, the Parties previously entered into an employment agreement effective September 7, 2012, as amended December 26, 2012 (the “Employment Agreement”); 
WHEREAS, the Company and Executive desire to amend certain provisions of the Employment Agreement related to severance benefits, as set forth below.
NOW, THEREFORE, for good and valuable consideration, the Parties agree that the Agreement is hereby amended as follows:
1.The Employment Agreement is hereby amended as follows:
A.The period at the end of the first sentence of Section 5(a) is replaced by the following:
“; provided, however, that if such Involuntary Termination occurs within twelve (12) months following a Change in Control (as defined in the Company’s 2013 Equity Incentive Plan), (i) Executive shall be entitled to a lump sum payment equal to Executive’s then-effective Base Salary and target bonus (less applicable withholding taxes) and (ii) if Executive elects continuation coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) within the time period prescribed pursuant to COBRA for Executive and Executive’s eligible dependents, the Company will reimburse Executive for the premiums necessary to continue  group health insurance benefits for Executive and Executive’s eligible dependents for a period of twelve (12) months following the date of Involuntary Termination, except that the right to future COBRA payments shall terminate the date upon which Executive ceases to be eligible for coverage under COBRA.”
B.Clause (A)(1) of Section 6(c) is hereby qualified in its entirety as follows:  the continuance of Executive’s duties and responsibilities at the subsidiary or divisional level following a Change in Control, rather than at the parent, combined or surviving company level following such Change in Control shall not be deemed Good Reason within the meaning of clause (A)(1).
2.Full Force and Effect.  To the extent not expressly amended hereby, the Agreement shall remain in full force and effect.
3.Entire Agreement.  This Amendment and the Agreement (and any other documents referenced therein) constitute the full and entire understanding and agreement between the Parties with regard to the subjects hereof and thereof.
4.Successors and Assigns.  This Amendment and the rights and obligations of the parties hereunder shall inure to the benefit of, and be binding upon, their respective successors, assigns, and legal representatives.
5.Governing Law.  This Amendment will be governed by the laws of the State of Washington (with the exception of its conflict of laws provisions).
(signature page follows)

IN WITNESS WHEREOF, each of the Parties has executed this Amendment as of the date set forth below.
	
		
	EXECUTIVE
	NANOSTRING TECHNOLOGIES, INC.

	By: /s/ James A. Johnson
	By: /s/ R. Bradley Gray

	Name: James A. Johnson
	Name: R. Bradley Gray

	 
	Title: President and Chief Executive Officer

	 
	 

	Date:  August 4, 2017
	Date:  August 4, 2017Exhibit

Exhibit 10.3
NANOSTRING TECHNOLOGIES, INC.
AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT
This Amendment to Executive Employment Agreement (this “Amendment”) is made by and between David Ghesquiere (“Executive”) and NanoString Technologies, Inc., a Delaware corporation (the “Company” and together with Executive, the “Parties”) on the dates set forth below.
WHEREAS, the Parties previously entered into an employment agreement effective November 20, 2013 (the “Employment Agreement”); 
WHEREAS, the Company and Executive desire to amend certain provisions of the Employment Agreement related to severance benefits, as set forth below.
NOW, THEREFORE, for good and valuable consideration, the Parties agree that the Agreement is hereby amended as follows:
1.The Employment Agreement is hereby amended as follows:
A.The period at the end of the first sentence of Section 5(a) is replaced by the following:
“; provided, however, that if such Involuntary Termination occurs within twelve (12) months following a Change in Control (as defined in the Company’s 2013 Equity Incentive Plan), (i) Executive shall be entitled to a lump sum payment equal to Executive’s then-effective Base Salary and target bonus (less applicable withholding taxes) and (ii) if Executive elects continuation coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) within the time period prescribed pursuant to COBRA for Executive and Executive’s eligible dependents, the Company will reimburse Executive for the premiums necessary to continue  group health insurance benefits for Executive and Executive’s eligible dependents for a period of twelve (12) months following the date of Involuntary Termination, except that the right to future COBRA payments shall terminate the date upon which Executive ceases to be eligible for coverage under COBRA.”
B.Clause (A)(1) of Section 6(c) is hereby qualified in its entirety as follows:  the continuance of Executive’s duties and responsibilities at the subsidiary or divisional level following a Change in Control, rather than at the parent, combined or surviving company level following such Change in Control shall not be deemed Good Reason within the meaning of clause (A)(1).
2.Full Force and Effect.  To the extent not expressly amended hereby, the Agreement shall remain in full force and effect.
3.Entire Agreement.  This Amendment and the Agreement (and any other documents referenced therein) constitute the full and entire understanding and agreement between the Parties with regard to the subjects hereof and thereof.
4.Successors and Assigns.  This Amendment and the rights and obligations of the parties hereunder shall inure to the benefit of, and be binding upon, their respective successors, assigns, and legal representatives.
5.Governing Law.  This Amendment will be governed by the laws of the State of Washington (with the exception of its conflict of laws provisions).
(signature page follows)

    
IN WITNESS WHEREOF, each of the Parties has executed this Amendment as of the date set forth below.
	
		
	EXECUTIVE
	NANOSTRING TECHNOLOGIES, INC.

	By: /s/ David W. Ghesquiere
	By: /s/ R. Bradley Gray

	Name: David W. Ghesquiere
	Name: R. Bradley Gray

	 
	Title: President and Chief Executive Officer

	 
	 

	Date:  August 4, 2017
	Date:  August 4, 2017EXHIBIT 10.26

SECOND AMENDMENT TO THE EXCLUSIVE AGREEMENT BETWEEN ABBOTT POINT OF CARE INC. AND ABAXIS, INC.

This Second Amendment (“Second Amendment”) to that certain Exclusive Agreement (“Agreement”) dated as of March 7, 2017, is effective as of April 19, 2017 (“Amendment Effective Date”) between Abaxis, Inc. (“ABAXIS”) and Abbott Point of Care Inc. (“ABBOTT”) relating to the appointment of ABBOTT to sell and distribute Abaxis Products. Any capitalized term used and not otherwise defined herein shall have the meaning set forth in the Agreement.

NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements contained herein, the Parties hereto, intending to be legally bound, hereby agree as follows:

		1	
Amendment. ABAXIS and ABBOTT hereby amend the Agreement as follows:

		a.	
Section 1.12 of the Agreement is amended and restated as follows:

		1.12.	
“Field” shall mean the professionally attended human healthcare market including Contract Research Organizations (CRO’s) but excluding the following: Catapult Health, LLC, pharmacy and retail store clinics, shopping malls, and cruise lines. The Field does not include use in the veterinary healthcare market.

		2.	
Miscellaneous. All terms and conditions set forth in the Agreement that are not amended hereby shall remain in full force and effect. This Second Amendment shall be governed by and construed in accordance with the substantive law of the State of Illinois, without regard to the conflicts of law provisions thereof, and any dispute arising out of or in connection with this Second Amendment shall be governed by the alternative dispute resolution provisions of Exhibit 9.11 of the Agreement. This Second Amendment may be executed in counterparts, each of which shall be deemed an original, but all of which will constitute one and the same instrument. This Second Amendment is the product of both of the Parties hereto and, in the event of a dispute over its interpretation, the language of this Second Amendment will not be construed against one Party in favor of the other. This Second Amendment together with the Agreement and the Amendment dated September 30, 2013 constitute the entire agreement between such Parties pertaining to the subject matter hereof, and merges all prior negotiations and drafts of the Parties with regard to the transactions contemplated herein. From the date hereof, any reference to the Agreement shall be deemed to refer to the Agreement as amended by this Second Amendment.

IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be executed by its authorized representative in its name and on its behalf.

	
ABBOTT POINT OF CARE INC.

	 	
ABAXIS, INC.

	 	 	 	 	 
	
By:

	
/s/ John Murad

	 	
By:

	
/s/ Donald P. Wood

	 	 	 	 	 
	
Name:

	
John Murad

	 	
Name:

	
Donald P. Wood

	 	 	 	 	 
	
Title:

	
Director, Channel Marketing

	 	
Title:

	
President & COO

	 	 	 	 	 
	
Date:

	
30-May-2017

	 	
Date:

	
5/23/17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00273-of-00352.parquet"}]]